According to two studies presented at a retina meeting, patients with macular edema related to retinal vein occlusion had significant improvement in vision when treated with ranibizumab (Lucentis) in each of two dosages. In trials including approximately 400 patients apiece, researchers from Johns Hopkins University and Houston's Methodist Hospital randomized patients to monthly 0.5 mg or 0.3 mg intravitreal injections of ranibizumab, or to sham injections, for six months. Notably, 46 to 47 percent of patients in both ranibizumab groups improved by at least 15 letters, compared with 16.9 percent of the control group.
Wednesday, October 07, 2009
Angiogenesis Inhibitor Works in Macular Edema
10:03 AM
Keshav Bhat
2 comments
2 comments:
can u give me some simple explanations about Branch retinal vein occlusion (BRVO)and central retinal vein occlusion (CRVO), and its differentials with artery occlusion (CRAO and BRAO)?
thx.
If your vascular system is functioning properly, the blood from the smaller branch veins will flow through one of the larger branch veins into the central retinal vein.However, sometimes, when an artery becomes hardened and is pressing down on an adjacent branch vein, the blood will not drain properly. When blood starts to collect in a branch vein, it increases pressure on the capillaries. This increased pressure will cause the capillaries to hemorrhage and leak blood onto the retina. This leakage can permanently damage the capillaries and impact the retina’s ability to absorb nutrients.
Central retinal vein occlusion is caused by an obstruction to the central retinal vein. The central retinal vein is the main vein that removes waste products from the eye.
If you have a central retinal vein occlusion, the neovascularization can lead to a vitreous hemorrhage and potential retinal detachment. If the neovascularization occurs on the iris, it can lead to neovascular glaucoma – the most serious complication of CRVO. Thus, CRVO can have serious implications for your vision.
Post a Comment